摘要 |
The present invention relates to the use of antibodies against the CD52 a ntigen, specifically monoclonal antibodies, for the production of medicament s for the treatment of diseases of the central nervous system, in particular transmissible spongiform encephalopathies, diseases that are also called pr ion diseases.
|